(Q42244133)

19 October 2017

title

Dual therapy with etravirine plus raltegravir for virologically suppressed HIV-infected patients: a pilot study (English)

1 reference

19 October 2017

0 references

1 reference

Polyana Monteiro

1

1 reference

19 October 2017

Iñaki Perez

2

1 reference

19 October 2017

Montserrat Laguno

3

1 reference

19 October 2017

Maria Martínez-Rebollar

4

1 reference

19 October 2017

Ana González-Cordon

5

1 reference

19 October 2017

Montserrat Lonca

6

1 reference

19 October 2017

Josep Mallolas

7

1 reference

19 October 2017

Jose L Blanco

8

1 reference

19 October 2017

Jose M Gatell

9

1 reference

19 October 2017

Esteban Martínez

10

1 reference

19 October 2017

language of work or name

English

0 references

publication date

14 October 2013

1 reference

Journal of Antimicrobial Chemotherapy

19 October 2017

published in

1 reference

19 October 2017

volume

69

1 reference

19 October 2017

issue

3

1 reference

19 October 2017

page(s)

742-748

1 reference

HIV infection, antiretroviral treatment, ageing, and non-AIDS related morbidity

19 October 2017

cites work

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKT406

Prevalence of comedications and effect of potential drug-drug interactions in the Swiss HIV Cohort Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKT406

Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKT406

Association between antiretroviral exposure and renal impairment among HIV-positive persons with normal baseline renal function: the D:A:D study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKT406

Raltegravir with optimized background therapy for resistant HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKT406

Efficacy and safety of etravirine at week 96 in treatment-experienced HIV type-1-infected patients in the DUET-1 and DUET-2 trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKT406

Trends in virological and clinical outcomes in individuals with HIV-1 infection and virological failure of drugs from three antiretroviral drug classes: a cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKT406

Premature age-related comorbidities among HIV-infected persons compared with the general population.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKT406

Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKT406

Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: the SPIRAL study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKT406

Web resources for HIV type 1 genotypic-resistance test interpretation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKT406

Quantification of the HIV-integrase inhibitor raltegravir (MK-0518) in human plasma by high-performance liquid chromatography with fluorescence detection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKT406

Lipid-lowering effect and efficacy after switching to etravirine in HIV-infected patients with intolerance to suppressive HAART.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKT406

Resistance profile of etravirine: combined analysis of baseline genotypic and phenotypic data from the randomized, controlled Phase III clinical studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKT406

TMC125 displays a high genetic barrier to the development of resistance: evidence from in vitro selection experiments

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKT406

Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKT406

Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKT406

Characterization of Genotypic and Phenotypic Changes in HIV-1-Infected Patients with Virologic Failure on an Etravirine-Containing Regimen in the DUET-1 and DUET-2 Clinical Studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKT406

Comparison of genotypic resistance profiles and virological response between patients starting nevirapine and efavirenz in EuroSIDA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKT406

Minimal pharmacokinetic interaction between the human immunodeficiency virus nonnucleoside reverse transcriptase inhibitor etravirine and the integrase inhibitor raltegravir in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKT406

Etravirine-raltegravir, a marked interaction in HIV-1-infected patients: about four cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKT406

Raltegravir dosage adjustment in HIV-infected patients receiving etravirine

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKT406

Acceptable plasma concentrations of raltegravir and etravirine when administered by gastrostomy tube in a patient with advanced multidrug-resistant human immunodeficiency virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKT406

The CD4/CD8 ratio as a marker T-cell activation, senescence and activation/exhaustion in treated HIV-infected children and young adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKT406

Minority variants associated with transmitted and acquired HIV-1 nonnucleoside reverse transcriptase inhibitor resistance: implications for the use of second-generation nonnucleoside reverse transcriptase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKT406

21 January 2018

Identifiers

DOI

10.1093/JAC/DKT406

1 reference

19 October 2017

1 reference